PURPOSE: To associate the global gene expression of B7/CD28 family transcripts with pathologic features of colon cancer, we determined the B7/CD28 family transcripts in peripheral blood mononuclear cells (PBMCs) from normal subjects and patients with adenomatous polyps and colon cancer, and correlated the results with pathologic features of colon cancer. METHODS: PBMCs from age-matched normal subjects and patients with adenomatous polyps and colon cancer were analyzed for peripheral blood transcripts (PBTs) of B7/CD28 family using real-time PCR. Differences in expression levels of B7/CD28 PBTs across all cancer stages and between colon cancer patients with or without microscopic lymphovascular invasion (LVI) were analyzed. RESULTS: The results showed a significant upregulation of PBTs of co-inhibitory molecules such as B7-H3 and PD-1 and a significant PBT downregulation of co-stimulatory molecules including CD28 and ICOS in colon cancer patients. Furthermore, the increase of B7-H3 PBT was strongly associated with tumor invasion (P = 0.025) and advanced TNM stages (P = 0.019), whereas the decline of co-stimulatory ligand B7-H2 PBT was related to regional lymph node metastasis (P = 0.028) and aggressive tumor invasion (P = 0.031). In addition, the ratios of PBT expression of CD28 family to B7 family such as CTLA-4 to B7-H2 and PD-1 to B7-H2 were significantly higher in colon cancer patients with microscopic LVI than in those without LVI (P = 0.001 and P = 0.016, respectively). CONCLUSIONS: Our results suggest that B7/CD28 family PBTs may serve as valuable markers reflecting the pathological features of colon cancer.
PURPOSE: To associate the global gene expression of B7/CD28 family transcripts with pathologic features of colon cancer, we determined the B7/CD28 family transcripts in peripheral blood mononuclear cells (PBMCs) from normal subjects and patients with adenomatous polyps and colon cancer, and correlated the results with pathologic features of colon cancer. METHODS: PBMCs from age-matched normal subjects and patients with adenomatous polyps and colon cancer were analyzed for peripheral blood transcripts (PBTs) of B7/CD28 family using real-time PCR. Differences in expression levels of B7/CD28PBTs across all cancer stages and between colon cancerpatients with or without microscopic lymphovascular invasion (LVI) were analyzed. RESULTS: The results showed a significant upregulation of PBTs of co-inhibitory molecules such as B7-H3 and PD-1 and a significant PBT downregulation of co-stimulatory molecules including CD28 and ICOS in colon cancerpatients. Furthermore, the increase of B7-H3 PBT was strongly associated with tumor invasion (P = 0.025) and advanced TNM stages (P = 0.019), whereas the decline of co-stimulatory ligand B7-H2 PBT was related to regional lymph node metastasis (P = 0.028) and aggressive tumor invasion (P = 0.031). In addition, the ratios of PBT expression of CD28 family to B7 family such as CTLA-4 to B7-H2 and PD-1 to B7-H2 were significantly higher in colon cancerpatients with microscopic LVI than in those without LVI (P = 0.001 and P = 0.016, respectively). CONCLUSIONS: Our results suggest that B7/CD28 family PBTs may serve as valuable markers reflecting the pathological features of colon cancer.
Authors: In-Hak Choi; Gefeng Zhu; Gabriel L Sica; Scott E Strome; John C Cheville; Julie S Lau; Yuwen Zhu; Dallas B Flies; Koji Tamada; Lieping Chen Journal: J Immunol Date: 2003-11-01 Impact factor: 5.422
Authors: Paul L Crispen; Yuri Sheinin; Timothy J Roth; Christine M Lohse; Susan M Kuntz; Xavier Frigola; R Houston Thompson; Stephen A Boorjian; Haidong Dong; Bradley C Leibovich; Michael L Blute; Eugene D Kwon Journal: Clin Cancer Res Date: 2008-08-11 Impact factor: 12.531
Authors: Tyler J Curiel; Shuang Wei; Haidong Dong; Xavier Alvarez; Pui Cheng; Peter Mottram; Roman Krzysiek; Keith L Knutson; Ben Daniel; Maria Carla Zimmermann; Odile David; Matthew Burow; Alan Gordon; Nina Dhurandhar; Leann Myers; Ruth Berggren; Akseli Hemminki; Ronald D Alvarez; Dominique Emilie; David T Curiel; Lieping Chen; Weiping Zou Journal: Nat Med Date: 2003-04-21 Impact factor: 53.440
Authors: Daniel L Barber; E John Wherry; David Masopust; Baogong Zhu; James P Allison; Arlene H Sharpe; Gordon J Freeman; Rafi Ahmed Journal: Nature Date: 2005-12-28 Impact factor: 49.962
Authors: R Houston Thompson; Susan M Kuntz; Bradley C Leibovich; Haidong Dong; Christine M Lohse; W Scott Webster; Shomik Sengupta; Igor Frank; Alexander S Parker; Horst Zincke; Michael L Blute; Thomas J Sebo; John C Cheville; Eugene D Kwon Journal: Cancer Res Date: 2006-04-01 Impact factor: 12.701
Authors: Stephen A Boorjian; Yuri Sheinin; Paul L Crispen; Sara A Farmer; Christine M Lohse; Susan M Kuntz; Bradley C Leibovich; Eugene D Kwon; Igor Frank Journal: Clin Cancer Res Date: 2008-08-01 Impact factor: 12.531
Authors: Iris Simon; Dionyssios Katsaros; Irene Rigault de la Longrais; Marco Massobrio; Andreas Scorilas; Nam W Kim; Mark J Sarno; Robert L Wolfert; Eleftherios P Diamandis Journal: Gynecol Oncol Date: 2007-05-11 Impact factor: 5.482
Authors: Martin Loos; Nathalia A Giese; Jörg Kleeff; Thomas Giese; Matthias M Gaida; Frank Bergmann; Melanie Laschinger; Markus W Büchler; Helmut Friess Journal: Cancer Lett Date: 2008-05-16 Impact factor: 8.679
Authors: Timothy J Roth; Yuri Sheinin; Christine M Lohse; Susan M Kuntz; Xavier Frigola; Brant A Inman; Amy E Krambeck; Maureen E McKenney; R Jeffrey Karnes; Michael L Blute; John C Cheville; Thomas J Sebo; Eugene D Kwon Journal: Cancer Res Date: 2007-08-08 Impact factor: 12.701
Authors: Zhiping Zhou; Neal Luther; George M Ibrahim; Cynthia Hawkins; Rajeev Vibhakar; Michael H Handler; Mark M Souweidane Journal: J Neurooncol Date: 2012-12-12 Impact factor: 4.130